UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000059859
Receipt number R000057458
Scientific Title Radio-Frequency-Ablation for lung cancer under general anesthesia
Date of disclosure of the study information 2025/11/24
Last modified on 2025/11/23 13:16:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Radio-Frequency-Ablation for lung cancer under general anesthesia

Acronym

Radio-Frequency-Ablation for lung cancer under general anesthesia

Scientific Title

Radio-Frequency-Ablation for lung cancer under general anesthesia

Scientific Title:Acronym

Radio-Frequency-Ablation for lung cance

Region

Japan


Condition

Condition

Malignant pulmonary tumors

Classification by specialty

Pneumology Hematology and clinical oncology Chest surgery
Radiology Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To increase accuracy of hitting radiofrequency ablation needle and decrease pain during the treatment.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Local control after radiofrequency ablation

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Before radiofrequency for malignant pulmonary tumors, general anesthesia with tracheal intubation is conducted at CT room, following by radiofrequency ablation.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Primary lung tumors or metastatic lung tumors.
2.The tumor is smaller than 5cm, and the number of tumors is less than 5.
3. Standard therapy, such as surgery, chemotherapy, and radiation therapy, is hard to control the tumor.
4. Patients request the radiofrequency ablation rather than the standard therapy, such as surgery, chemotherapy, and radiation therapy.
5. Patients with multiple metastatic tumors, who are expected to survival long after radiofrequency ablation for large lung tumors.
6. Performance status is lower than 2.

Key exclusion criteria

1. Severe clinical symptoms.
2. Unsuitable status judged by doctor in charge.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hiroaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Thoracic Surgery

Zip code

2770862

Address

617 Shikoda, Kashiwa-city, Chiba prefecture

TEL

0471451111

Email

hnomori@qk9.so-net.ne.jp


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Nomori

Organization

Kashiwa Kousei General Hospital

Division name

Thoracic Surgery

Zip code

2770862

Address

Shikoda 617, Kashiwa-city, Chiba prefecture

TEL

0471451111

Homepage URL

https://www.kashiwakousei.or.jp/medical/klokyukigeka/

Email

hnomori@qk9.so-net.ne.jp


Sponsor or person

Institute

Kashiwa Kousei General Hospital

Institute

Department

Personal name

Hiroaki Nomori, MD


Funding Source

Organization

None.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kashiwa Kousei General Hospital, Ethics Committee

Address

Shikoda 617, Kashiwa-city, Chiba prefecture

Tel

0471451111

Email

hnomori@qk9.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 11 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 03 Month 20 Day

Date of IRB

2023 Year 03 Month 20 Day

Anticipated trial start date

2023 Year 03 Month 20 Day

Last follow-up date

2035 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 11 Month 23 Day

Last modified on

2025 Year 11 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057458